Clinical effects and patient evaluations of ritexitinib (Lefenox) in the treatment of hair loss

Ritlecitinib is an oral, selective JAK3 tyrosine kinase inhibitor mainly used to treat patients with moderate to severe alopecia areata (Alopecia Areata, AA). By inhibiting the JAK-STAT signaling pathway, ritexitinib can reduce the immune-mediated inflammatory response of hair follicles and restore the normal growth cycle of hair follicles, thereby promoting hair regeneration. This drug is a new type of targeted therapy, especially suitable for patients who have failed to respond to traditional local or systemic immunosuppressive therapies.

Clinical studies have shown that ritexitinib is effective in moderate to severe alopecia areata patients, the treatment course is usually 24–48 weeks, approximately 30%–50% of patients can achieve significant scalp hair coverage (SALT score decrease ≥50%). In the early stage of treatment, most patients can observe signs of hair regeneration within the 12th to 16th week, and continued treatment can further increase hair density and coverage. Compared with traditional topical or systemic treatments, ritexitinib has a more rapid and significant effect.

In terms of patient reviews, most reported psychological improvements hair regrowth, such as increased self-esteem, reduced social anxiety, and improved quality of life. Some patients report that there are still plaques in early-stage hair sparse areas, but the overall improvement trend is obvious, and oral administration is convenient and easy to comply with. A few patients expressed concern about adverse drug reactions, such as mild hematological abnormalities or upper respiratory tract infections, but the drug was generally well tolerated.

In long-term management, patients need to regularly monitor blood routine, liver function and immune indicators under the guidance of doctors The dosage should be adjusted according to efficacy and tolerance. In clinical practice, ritixitinib is considered to be an effective targeted treatment option for patients with moderate to severe alopecia areata. It can not only improve appearance, but also significantly improve mental health and quality of life, providing new treatment hope for patients who are ineffective with traditional treatments.

Reference materials:https://www.drugs.com/